View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 21, 2021

India’s CDSCO approves emergency use of LumiraDx’s Covid-19 antigen test

The LumiraDx SARS-CoV-2 Antigen test received emergency use authorization from the FDA in August last year.

The Central Drugs Standard Control Organisation (CDSCO) in India has granted emergency use approval for LumiraDx’s SARS-CoV-2 Antigen test for the rapid diagnosis of Covid-19 in the country.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The microfluidic test has been designed for the detection of antigen nucleocapsid protein from a nasal swab. It provides results within 12 minutes of the sample application.

It can be run on the LumiraDx point of care (POC) platform, which integrates techniques that are used in laboratory analysers for delivering lab-comparable diagnostic tests on a single POC instrument.

The platform is made up of a microfluidic test strip; a small, portable instrument; standardised workflow; and digital connectivity to the Cloud and hospital IT systems.

The CDSCO’s approval is supported by clinical trials, which showed a positive agreement of 97.6% and negative agreement of 96.6% with the PCR test results of patients tested within 12 days of symptoms.

LumiraDx India general manager Yogesh Singh said: “There is a significant need for high-quality, accurate POC testing across India to meet not only the current demand with Covid-19, but also to provide testing for a number of health conditions beyond the pandemic.

“Launching the LumiraDx Platform and microfluidic technology, first with the SARS-CoV-2 Antigen test, will provide next-generation POC testing for patients in rural, urban and semi-urban health settings in India enabling healthcare providers to reduce the impact of acute and chronic diseases across the country.”

The LumiraDx SARS-CoV-2 Antigen test is already available in the US and Europe.

It received emergency use authorization (EUA) from the Food and Drug Administration (FDA) in August last year as well as the CE mark in Europe in September of the same year.

At present, the company has five tests on the market, including a portfolio of Covid-19 testing solutions, INR and D-Dimer tests. It is also developing tests for HbA1c, CRP, high sensitivity troponin I, Covid/Flu, and Tuberculosis.

LumiraDx also submitted an application to the FDA for EUA for its LumiraDx SARS-CoV-2 & Flu A/B Test.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network